Much has been discussed regarding the increasingly recognized limitations of phase III randomized trials in defining the future of cancer management and, indeed, there are many reasons to question whether there is genuine value in such efforts…More important, however, is another serious limitation of phase III randomized trial results in the oncology arena: how much do they actually influence clinical practice? (OncLive)